Human Bocavirus, a Respiratory and Enteric Virus

Diego Vicente,* Gustavo Cilla,* Milagrosa Montes,* Eduardo G. Pérez-Yarza,* and Emilio Pérez-Trallero†

In Spain, human bocavirus (HBoV) was detected in 48 (9.1%) of 527 children with gastroenteritis at similar frequency as for children with respiratory illness (40/520, 7.7%). Fecal excretion adds new concern about the transmission of HBoV. To our knowledge, this report is the first to document HBoV in human feces.

H
uman bocavirus (HBoV), a recently described new virus species belonging to the Paroviridae family, was identified as a human pathogen in September 2005 (1). Since then, this parvovirus has been found in children with respiratory tract illness in practically all areas of the world in which it has been investigated (2–5), an indication of its wide dissemination.

The Study

To determine the prevalence and clinical characteristics of HBoV, we investigated the presence of this virus in children with respiratory tract infection in our region (Gipúzkoa, Basque Country, Spain). Among the first patients in whom HBoV was detected in nasopharyngeal aspirates, we found two 12-month-old children with diarrhea in addition to respiratory symptoms. Because animal parvoviruses are frequently associated with enteritis in young animals (6), we investigated the presence of HBoV in the diarrheal feces of both children. HBoV was detected in both samples, and no other intestinal pathogens were identified. To rule out the possibility that this result could have been due to fecal contamination resulting from swallowing respiratory secretions, and to determine whether the gastrointestinal tract is affected by this new respiratory virus, we studied its presence in patient feces in 527 episodes of acute gastroenteritis, unrelated to respiratory infection, in children <3 years of age, mainly from nonhospital centers (ambulatory clinics). Our analyses were conducted from December 2005 through March 2006.

Viral DNA and RNA were obtained from nasopharyngeal aspirates and stool specimens with an automatic extractor BioRobot M48 (QIAGEN, Hilden, Germany) by using the MagAttract Virus Mini M48 kit (QIAGEN).

cDNA was obtained by using M-MuLV reverse transcriptase (Promega, Madison, WI, USA) and random primers. Aliquots of the DNA and cDNA were frozen at −40°C until PCR for HBoV detection was performed. Respiratory samples were investigated for respiratory syncytial virus, influenza viruses A and B, parainfluenza virus types 1–4, and adenovirus by cell culture and PCR. Rhinovirus, coronavirus (NL63 coronavirus included), and metapneumovirus were studied by PCR alone. Fecal specimens were examined for Shigella spp., Salmonella spp., Yersinia enterocolitica, Campylobacter spp., and enteroinvasive Escherichia coli O157 by standard culture methods. Rotavirus was investigated by enzyme immunoassay and norovirus by reverse transcriptase PCR. HBoV detection was performed by PCR with primers derived from the NP1 gene (7). Positive samples were retested and confirmed as positive by using a second PCR assay with primers derived from another location in the HBoV genome (VP1 gene) (7). Amplified NP1 and VP1 gene fragments (354 bp and 403 bp, respectively) were sequenced and analyzed by using the BLAST software (www.ncbi.nlm.nih.gov/BLAST). Each PCR run included a negative control (water) that was treated as the clinical sample throughout, and PCR was performed with the usual precautions to avoid contamination. Strain Spain001 (GenBank accession no. EF186830) was included as positive control in each PCR run.

Conclusions

Of the 527 stool samples analyzed from December 2005 through March 2006, HBoV was detected in 48 (9.1%). From a second group of 520 children <3 years of age who came to the pediatric emergency unit of our hospital with an episode of acute respiratory infection during the same period, a similar frequency of HBoV detection was obtained (40/520, 7.7%) when nasopharyngeal aspirates were tested. Analysis of NP1 and VP1 partial gene sequences obtained from all fecal and respiratory HBoV-positive samples showed a similarity of >95% with previously published HBoV sequences.

Of 40 HBoV-positive respiratory samples, 25 (62.5%) showed coinfection with other viruses (respiratory syncytial virus in 13, rhinovirus in 3, influenza A in 3, coronavirus OC43 in 2, adenovirus in 1, influenza B in 1, respiratory syncytial virus and coronavirus OC43 in 1, and influenza A and rhinovirus in 1). Of the 48 HBoV-positive fecal samples, 28 (58.3%) showed coinfection with another intestinal pathogen (Salmonella enteritidis in 1, Campylobacter jejuni in 5, rotavirus in 14, norovirus in 7, and C. jejuni and norovirus in 1).

In this study, simultaneous detection of HBoV and other agents was frequent for respiratory or enteric specimens. The incidence of coinfection in respiratory illness.
was similar to that observed in studies that were not limited to specimens that had already tested negative for other microorganisms and in which a wide number of agents were investigated (4). Adenoviruses have been associated with infection of the colon and the gut and are a cause of severe gastroenteritis in nonindustrialized countries. In this study, coinfection of adenovirus and HBoV was detected in 1 respiratory specimen but these viruses together were not detected in any fecal sample.

HBoV and parvovirus B19 are the only 2 species of the Parvoviridae family that have been associated with disease in humans. To date, HBoV has only been detected in samples from the respiratory tract and has been associated with both upper and lower respiratory tract disease in infants and young children. The results of our study show that HBoV is also present in the gastrointestinal tract in children with gastroenteritis with or without symptoms of respiratory infection. The fecal excretion adds new concern about the transmission of HBoV.

To our knowledge, this report is the first to document HBoV in human feces. The high frequency of HBoV detection in the feces of children with gastroenteritis and the absence of any other intestinal pathogen suggest that this new virus species is an enteric, as well as a respiratory, pathogen. Further investigations to confirm this preliminary hypothesis and gain greater knowledge of the association between HBoV and enteric disease are required.

This work was partly financed by the “Convenio Diputación Gipuzkoa-Hospital Donostia” and by a grant from the Spanish Ministerio de Sanidad y Consumo CIBER CB06/06.

Dr Vicente is a medical microbiologist at the Hospital Donostia, Gipuzkoa, Spain. His research focuses on viral respiratory infections and meningococcal infection epidemiology.

References
1. Allander T, Tammi MT, Eriksson M, Bjerkner A, Tiveljung-Lindell A, Andersson B. Cloning of a human parvovirus by molecular screening of respiratory tract samples. Proc Natl Acad Sci U S A. 2005;102:12891–6. Erratum Proc Natl Acad Sci U S A. 2005;102:15712.
2. Ma X, Endo R, Ishiguro N, Ebihara T, Ishiko H, Ariga T, et al. Detection of human bocavirus in Japanese children with lower respiratory tract infections. J Clin Microbiol. 2006;44:1132–4.
3. Arnold JC, Singh KK, Spector SA, Sawyer MH. Human bocavirus: prevalence and clinical spectrum at a children’s hospital. Clin Infect Dis. 2006;43:283–8.
4. Arden KE, McErlane P, Nissen MD, Sloots TP, Mackay IM. Frequent detection of human rhinoviruses, paramyxoviruses, coronaviruses, and bocavirus during acute respiratory tract infections. J Med Virol. 2006;78:1232–40.
5. Smuts H, Hardie D. Human bocavirus in hospitalized children, South Africa. Emerg Infect Dis. 2006;12:1457–8.
6. Durham PJ, Lax A, Johnson RH. Pathological and virological studies of experimental parvoviral enteritis in calves. Res Vet Sci. 1985;38:209–19.
7. Bastien N, Brandt K, Dust K, Ward D, Li Y. Human bocavirus infection, Canada. Emerg Infect Dis. 2006;12:848–50.

Address for correspondence: Emilio Pérez-Trallero, Hospital Donostia – Microbiology, Paseo Dr Beguiristain, s/n San Sebastian Gipuzkoa 20014, Spain; email: mikrobiol@terra.es

Instructions for Infectious Disease Authors

Dispatches
Articles should be no more than 1,200 words and need not be divided into sections. If subheadings are used, they should be general, e.g., “The Study” and “Conclusions.” Provide a brief abstract (50 words); references (not to exceed 15); figures or illustrations (not to exceed 2); tables (not to exceed 2); and a brief biographical sketch of first author—both authors if only 2. Dispatches are updates on infectious disease trends and research. The articles include descriptions of new methods for detecting, characterizing, or subtyping new or reemerging pathogens. Developments in antimicrobial drugs, vaccines, or infectious disease prevention or elimination programs are appropriate. Case reports are also welcome.

All material published in Emerging Infectious Diseases is in the public domain and may be used and reprinted without special permission; proper citation, however, is required.